New drug SRP-1005 takes first step against Huntington's

NCT ID NCT07536061

Recruiting now Disease control Sponsor: Sarepta Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called SRP-1005 in 32 adults with Huntington's disease. It is the first time this drug is being tested in humans, so the main goal is to check safety and how the body processes the drug. Participants will receive either SRP-1005 or a placebo by injection under the skin.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SRP-1005
What this could lead to: If this early trial shows safety, it could pave the way for a treatment that slows or controls Huntington's disease symptoms.
What could go wrong: This is a very early phase 1 study with only 32 participants, focused on safety and dosing. It is too soon to know if SRP-1005 will work, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUNTINGTON'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Huntington disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HUNTINGTON'S DISEASE

Contacts and locations

Locations

New Zealand Brain Research Institute
RECRUITING

Christchurch, 8014, New Zealand
Pacific Clinical Research Network - Auckland (PCRN Auckland)
NOT_YET_RECRUITING

Auckland, 622, New Zealand

More trials for these conditions

Other studies related to the condition(s) this trial covers.